Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 3/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | GHSR | Q92847 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1429692 | 0.88 | ALDH1A1 (0.45) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL12965681 | 0.88 | ALDH1A1 (0.45) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1429957 | 0.87 | KMT2A (0.44) | MEN1KMT2APKMMMP1MMP9 | |
| SCHEMBL13512952 | 0.85 | KMT2A (0.42) | MEN1KMT2APKMLMNA | |
| SCHEMBL1429882 | 0.84 | KMT2A (0.56) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Formic Acid SCHEMBL1429563 | 0.84 | ALDH1A1 (0.42) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2833646 | 0.83 | MEN1 (0.45) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2833162 | 0.83 | MEN1 (0.45) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2226510 | 0.83 | GHSR (0.47) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2832352 | 0.82 | PDK2 (0.45) | MEN1KMT2APKMEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735379-B2 | Fatty acid acetylated salicylates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8536183-B2 | 3-pyridylcarbonyl-piperazinylsulfonyl derivatives | Convergence Pharmaceuticals Limited (GB) | 2013-09-17 | — | — | US | disclosed |
| US-8536183-B2 | 3-pyridylcarbonyl-piperazinylsulfonyl derivatives | Convergence Pharmaceuticals Limited (GB) | 2013-09-17 | — | — | US | disclosed |
| US-8536183-B2 | 3-pyridylcarbonyl-piperazinylsulfonyl derivatives | Convergence Pharmaceuticals Limited (GB) | 2013-09-17 | — | — | US | disclosed |
| US-20120302746-A1 | 3-PYRIDYLCARBONYL-PIPERAZINYLSULFONYL DERIVATIVES | BESWICK PAUL JOHN (GB) | 2012-11-29 | — | — | US | disclosed |
| US-20120302746-A1 | 3-PYRIDYLCARBONYL-PIPERAZINYLSULFONYL DERIVATIVES | BESWICK PAUL JOHN (GB) | 2012-11-29 | — | — | US | disclosed |
| US-20120302746-A1 | 3-PYRIDYLCARBONYL-PIPERAZINYLSULFONYL DERIVATIVES | BESWICK PAUL JOHN (GB) | 2012-11-29 | — | — | US | disclosed |
| US-8288388-B2 | 3-pyridylcarbonyl-piperazinylsulfonyl derivatives | Convergence Pharmaceuticals Limited (GB) | 2012-10-16 | — | — | US | disclosed |
| US-8288388-B2 | 3-pyridylcarbonyl-piperazinylsulfonyl derivatives | Convergence Pharmaceuticals Limited (GB) | 2012-10-16 | — | — | US | disclosed |
| US-8288388-B2 | 3-pyridylcarbonyl-piperazinylsulfonyl derivatives | Convergence Pharmaceuticals Limited (GB) | 2012-10-16 | — | — | US | disclosed |
| EP-2300432-B1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | CONVERGENCE PHARMACEUTICALS (GB) | 2012-10-03 | — | — | EP | disclosed |
| EP-2300432-B1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | CONVERGENCE PHARMACEUTICALS (GB) | 2012-10-03 | — | — | EP | disclosed |
| EP-2300432-A1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | Convergence Pharmaceuticals Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20100022555-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20100022555-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20100022555-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-28 | — | — | US | disclosed |
| WO-2010007073-A1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022555-A1 | Novel Derivatives | CACNB2, CACNA1B, CACNA1D | HDAC3 1089/4885HDAC4 1574/4885HDAC1 1702/4885 |
| US-20120302746-A1 | 3-PYRIDYLCARBONYL-PIPERAZINYLSULFONYL DERIVATIVES | CACNB2, CACNA1C, KCNJ2 | HDAC3 400/4885HDAC4 1148/4885HDAC1 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.